| Journal: | Annals of hepatology |
| Database: | PERIÓDICA |
| System number: | 000414220 |
| ISSN: | 1665-2681 |
| Authors: | Ridruejo, Ezequiel1 Marciano, Sebastián2 Galdame, Omar2 Reggiardo, María V3 Muñoz, Alberto E4 Adrover, Raúl5 Cocozzella, Daniel5 Fernández, Nora6 Estepo, Claduio7 Mendizabal, Manuel8 Romero, Gustavo A4 Levi, Diana4 Schroder, Teresa7 Paz, Silvia7 Fainboim, Hugo7 Mandó, Iscar G1 Gadano, Adrián C2 Silva, Marcelo O8 |
| Institutions: | 1Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno", Departamento de Medicina, Buenos Aires. Argentina 2Hospital Italiano de Buenos Aires, Unidad de Hepatología y Trasplante Hepático, Buenos Aires. Argentina 3Hospital Provincial del Centenario, Unidad de Hepatología, Rosario, Santa Fe. Argentina 4Hospital Dr. Carlos Bonorino Udaondo, Unidad de Hepatología, Buenos Aires. Argentina 5Centro de Hepatología, Unidad de Hepatología, La Plata, Buenos Aires. Argentina 6Hospital Británico, Unidad de Hepatología, Buenos Aires. Argentina 7Hospital Francisco J. Muñiz, Unidad de Hepatología, Buenos Aires. Argentina 8Hospital Universitario Austral, Unidad de Hepatología y Trasplante Hepático, Pilar, Buenos Aires. Argentina |
| Year: | 2014 |
| Season: | May-Jun |
| Volumen: | 13 |
| Number: | 3 |
| Pages: | 327-336 |
| Country: | México |
| Language: | Inglés |
| Document type: | Artículo |
| Approach: | Analítico, descriptivo |
| English abstract | Background and aims. Entecavir (ETV) is effective and safe in patients with chronic hepatitis B in the short term, but its long term efficacy and safety has not been established. Material and methods. We evaluated HBV DNA clearance, HBeAg/antiHBe and HBsAg/antiHBs seroconversion rates in HBeAg-positive and negative NUC naïve HBV patients treated with ETV for more than 6 months, and predictors of response. Results. A hundred and sixty nine consecutive patients were treated with ETV for a median of 181 weeks. 61% were HBeAg positive, 23% were cirrhotics, and mean HBV-DNA levels were 6,88 ± 1,74 log10 IU/mL. Overall, 156 (92%) patients became HBV DNA undetectable, 92 (88%) HBeAg positive and 64 (98%) HBeAg negative patients. Seventy four (71%) patients cleared HBeAg after a median of 48 weeks of treatment, 23 (14%) patients cleared HBsAg (19 HBeAg positive and 4 HBeAg negative, p 0.025) after a median of 96 weeks of treatment, and 22 (13%) patients developed protective titers of anti-HBs. At the end of the study, 35 (20%) patients had discontinued therapy: 33 HBeAg positive and 2 HBeAg negative; 9 of them (26%) developed virological relapse after a median of 48 weeks of stopping treatment. None of the patients had primary non response and one patient developed breakthrough. Two patients developed HCC, three underwent liver transplantation and 3 deaths were attributable to liver-related events. No serious adverse events were reported. Conclusion. Long term ETV treatment showed high virological response rates, and a favorable safety profile for NUC-naive HBeAg-positive and negative patients treated in clinical practice |
| Disciplines: | Medicina |
| Keyword: | Farmacología, Gastroenterología, Terapéutica, Hepatitis B, Hepatitis crónica, Entecavir, Práctica clínica |
| Keyword: | Medicine, Gastroenterology, Pharmacology, Therapeutics, Hepatitis B, Chronic hepatitis, Entecavir, Clinical practice |
| Full text: | Texto completo (Ver PDF) |
